ETV2

Across TCGA pan-cancer cohorts, ETV2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ETV2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ETV2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ETV2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where ETV2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.488	0.930	<.001	45	view →
HNSC	DFS	Quartile	III,IV	1.000	0.862	.012	11	view →
LUAD	DFS	Tertile	All	0.651	0.926	.028	4	view →
LSCC	DFS	Quartile	III,IV	1.000	0.771	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ETV2–PDAC (DFS)

Open the PDAC breakdown →